Brief Communication: Personalized Circulating Tumor DNA as a Predictor of Pathologic Response in Neoadjuvant Treatment of Resectable Melanoma
{{output}}
Patients with resectable stage III-IV melanoma are at high risk of recurrence following surgical excision. Neoadjuvant therapy (NEO) with immune checkpoint inhibition (ICI) improves event-free survival and may allow for pathologic treatment response assessment... ...
